Clearside Biomedical Inc (NASDAQ:CLSD) CEO George M. Lasezkay purchased 12,000 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $1.16 per share, with a total value of $13,920.00. Following the completion of the transaction, the chief executive officer now owns 222,000 shares of the company’s stock, valued at approximately $257,520. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of CLSD traded down $0.02 during mid-day trading on Thursday, hitting $1.09. 4,960 shares of the company traded hands, compared to its average volume of 883,511. Clearside Biomedical Inc has a 1-year low of $0.56 and a 1-year high of $1.92. The company has a quick ratio of 3.47, a current ratio of 3.47 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $43.80 million, a PE ratio of -0.41 and a beta of -0.34. The business has a 50 day moving average of $0.90 and a 200 day moving average of $1.01.
Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). Clearside Biomedical had a negative net margin of 18,893.49% and a negative return on equity of 281.18%. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.05 million. As a group, research analysts expect that Clearside Biomedical Inc will post -0.84 EPS for the current fiscal year.
CLSD has been the subject of several analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Clearside Biomedical in a research report on Thursday, October 31st. Zacks Investment Research downgraded shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Monday. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. JMP Securities set a $3.00 price objective on shares of Clearside Biomedical and gave the company a “buy” rating in a report on Thursday, August 22nd. Finally, Wedbush restated a “buy” rating and set a $3.00 price objective on shares of Clearside Biomedical in a report on Monday, October 21st. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $2.33.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
Recommended Story: What is the Federal Reserve?
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.